Navigation Links
Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide

University College London and Hospital for Sick Kids purchase Open Access

to lentiviral RNAi libraries

HUNTSVILLE, Ala., March 26 /PRNewswire/ -- Open Biosystems, Inc., announced today that two leading research institutions, University College London (UCL), U.K., and the Hospital for Sick Kids, Toronto, Canada, have recently purchased access to Open Biosystems' shRNAmir technologies for RNAi by joining the Open Access RNAi(TM) Program.

(Logo: )

The Open Access Program, unique in this field, supports Open Biosystems' vision of supporting basic and medical research and reinforces its commitment to expanding access to research reagents for the life sciences community.

Both institutions purchased access to Open Biosystems' lentiviral shRNAmir libraries developed in collaboration with Drs Greg Hannon and Steve Elledge and exclusively distributed through Open Biosystems.

"Functional genomics is playing an ever important role in deciphering the roles of specific genes in cancer and developmental biology, as well as in neuro-sciences, infectious diseases and immunity. Open Biosystems' Open Access RNAi program helped foster this collaboration between the UCL Cancer Institute (hosting the new RNAi facility), UCL Institutes for Child Health and Neurology, and Division of Infection and Immunity, enabling us to provide world-class scientists in central London access to the latest shRNA libraries for focused functional screens, as well as stable knock-down experiments for pre-clinical models." said Dr. Chris Boshoff, Director, UCL Cancer Institute,

"Gene silencing using RNAi is gaining popularity around the world as researchers realize and witness its value both for understanding gene function and for the treatment of disease," said Brian Pollock, Chief Executive Officer at Open Biosystems. "By providing broad availability of RNAi resources across whole institutions, the Open Access Program creates a collaboration that encourages and supports scientific advancements."

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, the RNAi Consortium human and mouse lentiviral shRNA libraries as well as RNAi collections targeting Drosophila, C. elegans and Arabidopsis Thaliana. Participation in the Open Access RNAi program provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.

About Open Access RNAi

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced shRNA libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide. Complete details can be found at

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit

SOURCE Open Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
3. Open access to health research publications
4. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
5. Care reforms raise concerns over patient access to GP services
6. Access Innovations Provides Support Services for Agis Network
7. RAND researchers offer options to improve immigrant health care quality, access
8. Uninsured community health center patients often have difficulty accessing specialty services
9. Hispanics hypertension better controlled with equal access to care
10. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
11. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
Post Your Comments:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: